

ESHELMAN SCHOOL OF PHARMACY

Barriers and Facilitators to Effective & Equitable Cascade Screening

Megan C Roberts, PhD

Hereditary Conditions


Approximately 3% of us have rare genetic variants causing hereditary conditions that are *preventable* or *treatable* if diagnosed before symptoms develop.

- Lynch syndrome
- Hereditary Breast and Ovarian Cancer Syndrome
- Familial hypercholesterolemia
- Others




Cascade screening

Active process of identifying and testing relatives of individuals with a known hereditary condition



Cascade screening

Active process of identifying and testing relatives of individuals with a known hereditary condition




Currently, this isn't done well.



Implementation Science


The study of methods to promote the adoption and integration of evidence-based practices into routine health care and public health settings to improve the impact on population health.





Implementation Science

The study of methods to promote the adoption and integration of evidence-based practices into routine health care and public health settings to improve the impact on population health





Reviews

PRECISION MEDICINE

By Megan C. Roberts, W. David Dotson, Christopher S. DeVore, Erica M. Bednar, Deborah J. Bowen, Theodore G. Ganiats, Ridgely Fisk Green, Georgia M. Hurst, Alisdair R. Philp, Charité N. Ricker, Amy C. Sturm, Angela M. Trepanier, Janet L. Williams, Heather A. Zierhut, Katherine A. Wilemon, and Heather Hampel

- Reviewed literature from 1990-2017
- Described 45 statues and regulations

Delivery Of Cascade Screening For

Hereditary Conditions: European Journal of Human Genetics (2020) 28:1631–1644 https://doi.org/10.1038/s41431-020-00725-5 Review Of The Literatu REVIEW ARTICLE

ESHG



ABSTRACT Cascade screening is the process of conpeople who have been diagnosed with certain her purpose is to identify, inform, and manage those conducted a scoping review to obtain a broad over

Reviewed literature 2018

Barriers and facilitators for cascade testing in genetic conditions: a systematic review

Swetha Srinivasan 61 · Nae Yeon Won 62 · W. David Dotson 63 · Sarah T. Wright 64 · Megan C. Roberts 61

Received: 2 April 2020 / Revised: 21 August 2020 / Accepted: 1 September 2020 / Published online: 18 September 2020 © The Author(s), under exclusive licence to European Society of Human Genetics 2020

Abstract


Cascade testing is the process of offering genetic counseling and testing to at-risk relatives of an individual who has been diagnosed with a genetic condition. It is critical for increasing the identification rates of individuals with these conditions and the uptake of appropriate preventive health services. The process of cascade testing is highly varied in clinical practice, and a



Qualitative Study

PATIENTS (n=20)

- Adults with LS
- Family members of adults with LS



PROVIDERS (n=20)

- Genetic counselors
- Gastroenterologists
- Colorectal surgeons
- Oncologists
- Primary care physicians
- Gynecologic oncologists



ADMINISTRATORS (n=20)


- Genetics clinic managers
- Genetics labs
- Patient advocates


Payers





Findings-Consolidated Framework for Implementation Research (CFIR)







Barriers to Cascade Screening

Processes

Lack of processes






Barriers to cascade screening

Individuals Involved

- Knowledge
- Self-efficacy
- Other personal attributes






Enablers for cascade screening Individuals Involved Beliefs








Barriers to Cascade Screening

Inner Setting


Compatibility

Relative priority

Available resources









Barriers to Cascade Screening Outer Setting

External Policies








Barriers to Cascade Screening Intervention Characteristics

Costs
Complexity



Gaps in the Literature

Address geographic and communication barriers
Inclusion of implementation measures, methods and frameworks
Improved diversity of study populations
Utilization of rigorous study designs
Increase the number of US studies



Acknowledgements

Erica Bednar

Deb Bowen

Chris DeVore

Dave Dotson

Ridgley Fisk Green

Theodore Ganiats

Heather Hampel

Georgia Hurst

Alanna Kulchak Rahm

Jennifer Leeman

Amit Patel

Alisdair Philp

Daniel Reuland

Charite Ricker

Swetha Srinivasan

Amy Sturm

Angela Trepanier

Katherine Wilemon

Janet Williams

Nae Yeon Won

Sarah Wright

Heather Zierhut



Thank You.

